• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by YD Bio Limited

    1/20/26 8:32:14 PM ET
    $YDES
    Medical Specialities
    Health Care
    Get the next $YDES alert in real time by email
    6-K 1 ea0273361-6k_ydbio.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 6-K

     

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the Month of January 2026

     

    Commission File Number: 001-42810

     

     

     

    YD Bio Limited

     

     

     

    12F., No. 3, Xingnan St.,

    Nangang Dist.,

    Taipei City 115001, Taiwan

    (Address of principal executive offices)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒     Form 40-F ☐

     

     

     

     

     

     

    Appointment of Certain Directors 

     

    On January 16, 2026, the Board of Directors (the “Board”) of YD Bio Limited (the “Company”) approved the appointment of Dr. Chang as Chairman of the Compensation Committee and as a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee, effective immediately. Additionally, on January 16, 2026, the Board approved the appointment of Dr. Lu as Chairman of the Nominating and Corporate Governance Committee and as a member of the Company’s Audit Committee and Compensation Committee, effective immediately.

     

    Dr. Chang and Dr. Lu have no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K, and have no arrangement or understanding with any other person required to be disclosed pursuant to Item 401(a) of Regulation S-K. Dr. Chang and Dr. Lu have no family relationships required to be disclosed pursuant to Item 401(d) of Regulation S-K.

     

    Additionally, on January 20, 2026, the Company notified Nasdaq that the Company has regained compliance with the requirements for the Audit Committee pursuant to Nasdaq Listing Rule 5605, and that the Company is no longer subject to the cure period under Nasdaq Listing Rule 5605(c)(4)(B).

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    January 21, 2026

     

      YD BIO LIMITED
       
      By: /s/ Edmund Hen
      Name:  Edmund Hen
      Title: Chief Financial Officer

     

     

    2

     

     

    Get the next $YDES alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $YDES

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $YDES
    SEC Filings

    View All

    SEC Form 424B3 filed by YD Bio Limited

    424B3 - YD Bio Ltd (0002011674) (Filer)

    2/27/26 10:12:20 AM ET
    $YDES
    Medical Specialities
    Health Care

    SEC Form 6-K filed by YD Bio Limited

    6-K - YD Bio Ltd (0002011674) (Filer)

    2/26/26 2:00:33 PM ET
    $YDES
    Medical Specialities
    Health Care

    SEC Form 424B3 filed by YD Bio Limited

    424B3 - YD Bio Ltd (0002011674) (Filer)

    2/5/26 4:07:51 PM ET
    $YDES
    Medical Specialities
    Health Care

    $YDES
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 3 filed by new insider Lu Shao-Ta

    3/A - YD Bio Ltd (0002011674) (Issuer)

    4/20/26 11:47:42 AM ET
    $YDES
    Medical Specialities
    Health Care

    SEC Form 4 filed by Lu Shao-Ta

    4 - YD Bio Ltd (0002011674) (Issuer)

    4/2/26 4:03:32 PM ET
    $YDES
    Medical Specialities
    Health Care

    SEC Form 4 filed by Chang Kochi

    4 - YD Bio Ltd (0002011674) (Issuer)

    4/2/26 4:03:31 PM ET
    $YDES
    Medical Specialities
    Health Care

    $YDES
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

    Taipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd., a Taiwan registered company ("EG BioMed"), officially launched the EG Telehealth Platform, https://mdi.eg-bio.com, which marks a significant milestone in the Company's commercialization of early cancer detection and decentralized clinical service delivery across the United States. The platform is now live and enables access across 44 U.S. states, plus Washington, D.C. and Guam, supported by a nationwide network

    3/31/26 8:00:00 AM ET
    $YDES
    Medical Specialities
    Health Care

    YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem

    Taipei, Taiwan, March 17, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today highlighted the strategic roadmap shared by CEO Dr. Ethan Shen in a recent interview with PharmaBoardroom, a UK-based platform providing insights to the global healthcare and life sciences community. Moving beyond the traditional single-asset biotech model, YD Bio Ltd is building a comprehensive ecosystem that synchronizes diagnostic intelligence with advanced therapeutic execution. In the interview, Dr. Shen addressed the Company's approach to the biotech

    3/17/26 8:00:00 AM ET
    $YDES
    Medical Specialities
    Health Care

    YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform

    Taipei, Taiwan, Feb. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its subsidiary YD Bio USA, Inc. ("YD Bio USA") entered into a Master Strategic Alliance Agreement (the "Agreement") with YC Biotech Co., Ltd. ("YC Biotech") on February 24, 2026. This partnership represents a pivotal advancement in the Company's mission, establishing YD Bio USA as the official strategic hub and exclusive U.S. Agent for regulatory applications to the U.S. Food and Drug Administration (the "FDA") for YC Biotech's Contract Research

    2/25/26 8:00:00 AM ET
    $YDES
    Medical Specialities
    Health Care